{"id":464,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"elamipretide-barth-syndrome-trial-fda-accelerated-approval","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","title":{"rendered":"Elamipretide \u0641\u064a \u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b: \u0645\u0627 \u0623\u0638\u0647\u0631\u062a\u0647 \u062a\u062c\u0631\u0628\u0629 12 \u0644\u0644\u0645\u0631\u064a\u0636 \u0648\u0633\u062c\u0644 FDA"},"content":{"rendered":"

\u0644\u062f\u0649 Elamipretide \u0627\u0644\u0622\u0646 \u0645\u0646\u062a\u062c \u0646\u0647\u0627\u0626\u064a \u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA \u0644\u0645\u0624\u0634\u0631 \u0636\u064a\u0642 \u0644\u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b\u060c \u0644\u0643\u0646 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0645\u062c\u0645\u0648\u0639\u0629 \u0628\u064a\u0627\u0646\u0627\u062a \u063a\u064a\u0631 \u0639\u0627\u062f\u064a\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0646\u0627\u062f\u0631\u0629. \u0634\u0645\u0644 \u0627\u0644\u062c\u0632\u0621 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u0641\u064a 12 \u0648\u0644\u0645 \u064a\u0633\u062a\u0648\u0641 \u0646\u0642\u0637\u062a\u064a \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u062a\u064a\u0646.<\/p>

\u0645\u0627 \u064a\u0638\u0647\u0631\u0647 \u0627\u0644\u0633\u062c\u0644<\/h2>
  • \u0643\u0627\u0646 \u062c\u0645\u064a\u0639 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u064a\u0646 \u0641\u064a 12 \u0645\u0646 \u0627\u0644\u0630\u0643\u0648\u0631\u060c \u0627\u0644\u0630\u064a\u0646 \u062a\u062a\u0631\u0627\u0648\u062d \u0623\u0639\u0645\u0627\u0631\u0647\u0645 \u0628\u064a\u0646 12 \u0625\u0644\u0649 35\u060c \u0641\u064a \u0645\u0648\u0642\u0639 US \u0648\u0627\u062d\u062f.<\/li>
  • \u0644\u0645 \u062a\u0638\u0647\u0631 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u062a\u0641\u0648\u0642\u064b\u0627 \u0639\u0644\u0649 \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 6 \u0627\u0644\u062a\u064a \u062a\u0628\u0644\u063a \u062f\u0642\u064a\u0642\u0629 \u0633\u064a\u0631\u064b\u0627 \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u062f\u0627\u0645 \u0623\u0648 \u0627\u0644\u062a\u0639\u0628.<\/li>
  • \u0645\u0646\u062d\u062a FDA \u0645\u0648\u0627\u0641\u0642\u0629 \u0633\u0631\u064a\u0639\u0629 \u0628\u0646\u0627\u0621\u064b \u0639\u0644\u0649 \u0642\u0648\u0629 \u0627\u0644\u0628\u0627\u0633\u0637\u0629 \u0644\u0644\u0631\u0643\u0628\u0629 \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0644\u0627\u062d\u0638\u062a\u0647\u0627 \u062e\u0644\u0627\u0644 \u0645\u062a\u0627\u0628\u0639\u0629 \u0623\u0637\u0648\u0644 \u0644\u0644\u0639\u0644\u0627\u0645\u0629 \u0627\u0644\u0645\u0641\u062a\u0648\u062d\u0629 \u0648\u062a\u0637\u0644\u0628\u062a \u062a\u062c\u0631\u0628\u0629 \u062a\u0623\u0643\u064a\u062f\u064a\u0629.<\/li><\/ul><\/div><\/div>
    \"\u0639\u0627\u0644\u0645
    \u0627\u0644\u062a\u0648\u0636\u064a\u062d \u0627\u0644\u062a\u062d\u0631\u064a\u0631\u064a \u0627\u0644\u0623\u0635\u0644\u064a \u0644\u0633\u064a\u0627\u0642 \u0627\u0644\u0628\u062d\u062b. \u0625\u0646\u0647\u0627 \u0644\u064a\u0633\u062a \u0634\u062e\u0635\u064a\u0629 \u062f\u0631\u0627\u0633\u064a\u0629 \u0623\u0648 \u0635\u0648\u0631\u0629 \u0645\u0631\u064a\u0636 \u0623\u0648 \u0635\u0648\u0631\u0629 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0645\u0648\u0631\u062f\u0629 \u0623\u0648 \u062a\u0645\u062b\u064a\u0644 \u0644\u0645\u0648\u0627\u062f \u062a\u062c\u0631\u064a\u0628\u064a\u0629.<\/figcaption><\/figure>

    \u0633\u062c\u0644 \u0627\u0644\u062f\u0631\u0627\u0633\u0629<\/h2>

    \u0642\u0627\u0631\u0646\u062a \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u062a\u0642\u0627\u0637\u0639\u0629 \u0641\u062a\u0631\u0627\u062a 12 \u0644\u0645\u062f\u0629 \u0623\u0633\u0628\u0648\u0639 \u0645\u0646 \u0627\u0644\u0625\u0644\u0627\u0645\u0628\u0631\u064a\u062a\u064a\u062f \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a\u060c \u0645\u0641\u0635\u0648\u0644\u0629 \u0628\u0627\u0644\u063a\u0633\u0644. \u062f\u062e\u0644 \u0639\u0634\u0631\u0629 \u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u0641\u064a \u0627\u0645\u062a\u062f\u0627\u062f \u0627\u0644\u062a\u0633\u0645\u064a\u0629 \u0627\u0644\u0645\u0641\u062a\u0648\u062d\u0629 \u0648\u062a\u0645\u062a \u0645\u062a\u0627\u0628\u0639\u0629 \u062b\u0645\u0627\u0646\u064a\u0629 \u0645\u0646\u0647\u0645 \u062e\u0644\u0627\u0644 \u0627\u0644\u0623\u0633\u0628\u0648\u0639 168.<\/p>

    \u0627\u0644\u0633\u0643\u0627\u0646 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u064a\u0646<\/strong>12 \u0645\u0631\u0636\u0649 \u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b \u0627\u0644\u0645\u0624\u0643\u062f\u064a\u0646 \u0648\u0631\u0627\u062b\u064a\u0627<\/span><\/div>
    \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629<\/strong>6 \u0645\u0633\u0627\u0641\u0629 \u062f\u0642\u064a\u0642\u0629 \u0633\u064a\u0631\u064b\u0627 \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u062f\u0627\u0645 \u0648\u062f\u0631\u062c\u0629 \u0627\u0644\u062a\u0639\u0628 \u0627\u0644\u0625\u062c\u0645\u0627\u0644\u064a\u0629<\/span><\/div>
    \u0627\u0644\u0646\u062a\u064a\u062c\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629<\/strong>\u0644\u0645 \u062a\u062c\u062a\u0645\u0639 \u0623\u064a \u0645\u0646 \u0646\u0642\u0637\u062a\u064a \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0641\u064a \u062c\u0632\u0621 \u0627\u0644\u062a\u0642\u0627\u0637\u0639 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a<\/span><\/div>
    \u062a\u0627\u0631\u064a\u062e \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629<\/strong>\u0633\u0628\u062a\u0645\u0628\u0631 19\u060c 2025<\/span><\/div>
    \u0646\u0648\u0639 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629<\/strong>\u0645\u0639\u062c\u0644 \u0645\u0637\u0644\u0648\u0628 \u0645\u062d\u0627\u0643\u0645\u0629 \u062a\u0623\u0643\u064a\u062f\u064a\u0629<\/span><\/div><\/div><\/div>

    \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0641\u064a \u0627\u0644\u0633\u064a\u0627\u0642<\/h2>

    \u062a\u0634\u064a\u0631 FDA \u0625\u0644\u0649 \u0645\u062a\u0648\u0633\u0637 \u200b\u200b\u0642\u0648\u0629 \u0628\u0627\u0633\u0637\u0629 \u0627\u0644\u0631\u0643\u0628\u0629 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u0629 \u0627\u0644\u062a\u064a \u062a\u0628\u0644\u063a 124 \u0646\u064a\u0648\u062a\u0646. \u0643\u0627\u0646\u062a \u0627\u0644\u062a\u063a\u064a\u064a\u0631\u0627\u062a \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u0629 \u0641\u064a \u0627\u0644\u0623\u0633\u0628\u0648\u0639 12 \u0647\u064a \u22125 \u0646\u064a\u0648\u062a\u0646 \u0639\u0644\u0649 \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a \u0648+4 \u0639\u0644\u0649 \u0627\u0644\u0625\u0644\u0627\u0645\u0628\u0631\u064a\u062a\u064a\u062f\u061b \u0638\u0647\u0631\u062a \u062a\u063a\u064a\u064a\u0631\u0627\u062a \u0648\u0635\u0641\u064a\u0629 \u0623\u0643\u0628\u0631 \u0623\u062b\u0646\u0627\u0621 \u0627\u0645\u062a\u062f\u0627\u062f \u0627\u0644\u062a\u0633\u0645\u064a\u0629 \u0627\u0644\u0645\u0641\u062a\u0648\u062d\u0629\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 +63 \u0646\u064a\u0648\u062a\u0646 \u0628\u064a\u0646 \u062b\u0645\u0627\u0646\u064a\u0629 \u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u0641\u064a \u0627\u0644\u0623\u0633\u0628\u0648\u0639 168.<\/p>

    \u064a\u0643\u0648\u0646 \u062a\u063a\u064a\u064a\u0631 \u0627\u0644\u062a\u0633\u0645\u064a\u0629 \u0627\u0644\u0645\u0641\u062a\u0648\u062d\u0629 \u0639\u0631\u0636\u0629 \u0644\u062a\u0623\u062b\u064a\u0631\u0627\u062a \u0627\u0644\u0648\u0642\u062a \u0648\u0627\u0644\u062a\u0648\u0642\u0639\u0627\u062a \u0648\u0627\u0644\u0627\u0633\u062a\u0645\u0631\u0627\u0631 \u0627\u0644\u0627\u0646\u062a\u0642\u0627\u0626\u064a \u0648\u063a\u064a\u0627\u0628 \u0627\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0645\u062a\u0632\u0627\u0645\u0646. \u0644\u0630\u0644\u0643\u060c \u064a\u062a\u0637\u0644\u0628 FDA \u062a\u0623\u0643\u064a\u062f\u064b\u0627 \u0628\u0639\u062f \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 \u0623\u0646 \u062a\u063a\u064a\u064a\u0631 \u0627\u0644\u0642\u0648\u0629 \u064a\u062a\u0631\u062c\u0645 \u0625\u0644\u0649 \u0641\u0627\u0626\u062f\u0629 \u0644\u0644\u0645\u0631\u064a\u0636.<\/p>

    \u0645\u0627 \u0644\u0627 \u062a\u0633\u062a\u0637\u064a\u0639 \u0647\u0630\u0647 \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0625\u062c\u0627\u0628\u0629 \u0639\u0644\u064a\u0647<\/h2>

    \u0645\u062c\u0645\u0648\u0639\u0629 \u0627\u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0635\u063a\u064a\u0631\u0629 \u0644\u0644\u063a\u0627\u064a\u0629 \u0648\u0644\u0627 \u064a\u0645\u0643\u0646\u0647\u0627 \u062f\u0639\u0645 \u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u0645\u062c\u0645\u0648\u0639\u0627\u062a \u0627\u0644\u0641\u0631\u0639\u064a\u0629.<\/p>

    \u062a\u0646\u0637\u0628\u0642 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 Forzinity \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b \u0648\u064a\u0632\u0646\u0648\u0646 \u0645\u0627 \u0644\u0627 \u064a\u0642\u0644 \u0639\u0646 30 \u0643\u062c\u0645 - \u0648\u0644\u064a\u0633 \u0639\u0644\u0649 \u0627\u0644\u0645\u0648\u0627\u062f \u0627\u0644\u0639\u0627\u0645\u0629 \"SS-31\" \u0623\u0648 \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645\u0627\u062a \u0627\u0644\u0623\u062e\u0631\u0649.<\/p>","protected":false},"excerpt":{"rendered":"

    \u0644\u062f\u0649 Elamipretide \u0627\u0644\u0622\u0646 \u0645\u0646\u062a\u062c \u0646\u0647\u0627\u0626\u064a \u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA \u0644\u0645\u0624\u0634\u0631 \u0636\u064a\u0642 \u0644\u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b\u060c \u0644\u0643\u0646 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0645\u062c\u0645\u0648\u0639\u0629 \u0628\u064a\u0627\u0646\u0627\u062a \u063a\u064a\u0631 \u0639\u0627\u062f\u064a\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0646\u0627\u062f\u0631\u0629. \u0634\u0645\u0644 \u0627\u0644\u062c\u0632\u0621 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u0641\u064a 12 \u0648\u0644\u0645 \u064a\u0633\u062a\u0648\u0641 \u0646\u0642\u0637\u062a\u064a \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u062a\u064a\u0646.<\/p>","protected":false},"author":1,"featured_media":629,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Published study case","pim_evidence_level":"Small randomized crossover trial plus FDA accelerated-approval record","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nElamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD<\/title>\n<meta name=\"description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ar\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\" \/>\n<meta property=\"og:description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ar\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/ar\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Elamipretide \u0641\u064a \u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b: \u0645\u0627 \u0627\u0644\u0630\u064a \u0623\u0638\u0647\u0631\u062a\u0647 \u062a\u062c\u0631\u0628\u0629 12 \u0644\u0644\u0645\u0631\u064a\u0636 \u0648\u0633\u062c\u0644 FDA - NHD","description":"\u0644\u062f\u0649 Elamipretide \u0627\u0644\u0622\u0646 \u0645\u0646\u062a\u062c \u0646\u0647\u0627\u0626\u064a \u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA \u0644\u0645\u0624\u0634\u0631 \u0636\u064a\u0642 \u0644\u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b\u060c \u0644\u0643\u0646 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0645\u062c\u0645\u0648\u0639\u0629 \u0628\u064a\u0627\u0646\u0627\u062a \u063a\u064a\u0631 \u0639\u0627\u062f\u064a\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0646\u0627\u062f\u0631\u0629. \u0630\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ar\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","og_locale":"ar_AR","og_type":"article","og_title":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","og_description":"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026","og_url":"https:\/\/nhdbio.com\/ar\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"NHD Technical Team","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"ar","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","url":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","name":"Elamipretide \u0641\u064a \u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b: \u0645\u0627 \u0627\u0644\u0630\u064a \u0623\u0638\u0647\u0631\u062a\u0647 \u062a\u062c\u0631\u0628\u0629 12 \u0644\u0644\u0645\u0631\u064a\u0636 \u0648\u0633\u062c\u0644 FDA - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"\u0644\u062f\u0649 Elamipretide \u0627\u0644\u0622\u0646 \u0645\u0646\u062a\u062c \u0646\u0647\u0627\u0626\u064a \u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA \u0644\u0645\u0624\u0634\u0631 \u0636\u064a\u0642 \u0644\u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u0628\u0627\u0631\u062b\u060c \u0644\u0643\u0646 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0645\u062c\u0645\u0648\u0639\u0629 \u0628\u064a\u0627\u0646\u0627\u062a \u063a\u064a\u0631 \u0639\u0627\u062f\u064a\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0646\u0627\u062f\u0631\u0629. \u0630\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u0645\u0648\u0627\u062f \u062e\u0627\u0645 \u0628\u0628\u062a\u064a\u062f\u064a\u0629 \u0648\u062a\u062e\u0644\u064a\u0642 \u0627\u0644\u0628\u0628\u062a\u064a\u062f\u0627\u062a \u062d\u0633\u0628 \u0627\u0644\u0637\u0644\u0628","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u0627\u0644\u0641\u0631\u064a\u0642 \u0627\u0644\u0641\u0646\u064a NHD","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"\u064a\u062d\u062a\u0641\u0638 \u0641\u0631\u064a\u0642 NHD \u0627\u0644\u0641\u0646\u064a \u0628\u0648\u062b\u0627\u0626\u0642 \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0628\u062d\u062b\u064a \u0648\u0645\u0644\u062e\u0635\u0627\u062a \u0627\u0644\u0623\u062f\u0644\u0629. \u062a\u0631\u062a\u0628\u0637 \u0627\u0644\u0645\u0642\u0627\u0644\u0627\u062a \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0628\u0627\u0644\u0623\u0648\u0631\u0627\u0642 \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0645\u0646 \u0642\u0628\u0644 \u0627\u0644\u0646\u0638\u0631\u0627\u0621\u060c \u0648\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0648\u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629\u060c \u0648\u062a\u062d\u062a\u0641\u0638 \u0628\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0641\u0627\u0631\u063a\u0629 \u0648\u0642\u064a\u0648\u062f \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u0648\u062a\u0645\u064a\u0632 \u0627\u0644\u062a\u062f\u062e\u0644\u0627\u062a \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0629 \u0639\u0646 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c. \u064a\u0645\u0643\u0646 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0628\u0645\u0633\u0627\u0639\u062f\u0629 AI \u0644\u0644\u0647\u064a\u0643\u0644\u061b \u062a\u0638\u0644 \u0631\u0648\u0627\u0628\u0637 \u0627\u0644\u0645\u0635\u062f\u0631 \u0648\u062d\u062f\u0648\u062f \u0627\u0644\u0623\u062f\u0644\u0629 \u0645\u0631\u0626\u064a\u0629. \u0647\u0630\u0627 \u0627\u0644\u0639\u0645\u0644 \u0644\u064a\u0633 \u0645\u0631\u0627\u062c\u0639\u0629 \u0623\u0642\u0631\u0627\u0646 \u0645\u0633\u062a\u0642\u0644\u0629 \u0623\u0648 \u0646\u0635\u064a\u062d\u0629 \u0637\u0628\u064a\u0629.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/ar\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/comments?post=464"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/464\/revisions"}],"predecessor-version":[{"id":512,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/464\/revisions\/512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media\/629"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media?parent=464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/categories?post=464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/tags?post=464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}